AstraZeneca Shares Outstanding 2006-2018 | AZN

AstraZeneca shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • AstraZeneca shares outstanding for the quarter ending September 30, 2018 were 2.534B, a 0.08% increase year-over-year.
  • AstraZeneca 2017 shares outstanding were 2.534B, a 0.08% increase from 2016.
  • AstraZeneca 2016 shares outstanding were 2.532B, a 0.08% increase from 2015.
  • AstraZeneca 2015 shares outstanding were 2.53B, a 0.08% increase from 2014.
AstraZeneca Annual Shares Outstanding
(Millions of Shares)
2017 2,534
2016 2,532
2015 2,530
2014 2,528
2013 2,508
2012 2,528
2011 2,734
2010 2,892
2009 2,900
2008 2,906
2007 2,996
2006 3,140
2005 3,236
AstraZeneca Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 2,534
Q2 2018 2,534
Q1 2018 2,532
Q4 2017 2,534
Q3 2017 2,532
Q2 2017 2,534
Q1 2017 2,532
Q4 2016 2,532
Q3 2016 2,532
Q2 2016 2,530
Q1 2016 2,530
Q4 2015 2,530
Q3 2015 2,530
Q2 2015 2,530
Q1 2015 2,530
Q4 2014 2,528
Q3 2014 2,528
Q2 2014 2,528
Q1 2014 2,524
Q4 2013 2,508
Q3 2013 2,508
Q2 2013 2,508
Q1 2013 2,500
Q4 2012 2,528
Q3 2012 2,504
Q2 2012 2,538
Q1 2012 2,570
Q4 2011 2,634
Q3 2011 2,718
Q2 2011 2,774
Q1 2011 2,808
Q4 2010 2,852
Q3 2010 2,892
Q2 2010 2,900
Q1 2010 2,904
Q4 2009 2,910
Q3 2009 2,897
Q2 2009 2,893
Q1 2009 2,896
Q4 2008 2,907
Q3 2008 2,910
Q2 2008 2,912
Q1 2008 2,914
Q4 2007 2,977
Q3 2007 2,945
Q2 2007 2,947
Q1 2007 3,067
Q4 2006 3,090
Q3 2006 3,138
Q2 2006 3,160
Q1 2006 3,164
Q4 2005 3,184
Q3 2005 3,226
Q2 2005 3,253
Q1 2005 3,311
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $103.342B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $396.345B 18.58
Pfizer (PFE) United States $262.998B 14.83
Merck (MRK) United States $205.854B 17.84
Novartis AG (NVS) Switzerland $204.655B 17.49
AbbVie (ABBV) United States $134.597B 11.95
Eli Lilly (LLY) United States $122.680B 21.57
Sanofi (SNY) France $112.713B 13.96
Novo Nordisk (NVO) Denmark $111.107B 18.04
GlaxoSmithKline (GSK) United Kingdom $101.256B 13.61
Bristol-Myers Squibb (BMY) United States $87.290B 14.38